FTI-2153 TFA

• CAT Number: I045505
• CAS Number: 2820151-01-5
• Molecular Formula: C27H31F3N4O5S
• Molecular Weight: 580.62
• Purity: ≥95%
• Synonyms: methyl (2S)-2-[[4-[(1H-imidazol-5-ylmethylamino)methyl]-2-(2-methylphenyl)benzoyl]amino]-4-methylsulfanylbutanoate;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C25H30N4O3S.C2HF3O2/c1-17-6-4-5-7-20(17)22-12-18(13-26-14-19-15-27-16-28-19)8-9-21(22)24(30)29-23(10-11-33-3)25(31)32-2;3-2(4,5)1(6)7/h4-9,12,15-16,23,26H,10-11,13-14H2,1-3H3,(H,27,28)(H,29,30);(H,6,7)/t23-;/m0./s1
• InChIKey: LRKNQRCLUQTFRP-BQAIUKQQSA-N
• SMILES: CC1=CC=CC=C1C2=C(C=CC(=C2)CNCC3=CN=CN3)C(=O)NC(CCSC)C(=O)OC.C(=O)(C(F)(F)F)O

FTI-2153 TFA (Cat No.: I045505) is a farnesyltransferase inhibitor that blocks the post-translational farnesylation of proteins such as Ras, a modification essential for their membrane localization and oncogenic activity. By preventing farnesylation, FTI-2153 disrupts Ras-driven signaling pathways involved in cell proliferation, survival, and differentiation. The trifluoroacetic acid (TFA) salt form improves solubility and handling. FTI-2153 TFA is primarily used in cancer research to study Ras-related oncogenesis, signal transduction, and the development of targeted therapies for Ras-dependent tumors and other farnesyltransferase-related diseases.

Reference

[1]. Sun J, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999 Oct 1;59(19):4919-26.
[Content Brief]

[2]. N C Crespo, et al. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ. 2002 Jul;9(7):702-9.
[Content Brief]